Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
14.69 USD +2.08% Intraday chart for CVRx, Inc. -1.41% -53.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024 CI
CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024 CI
JPMorgan Raises CVRx's Price Target to $36 From $31, Keeps Overweight Rating MT
CVRx Q4 Net Loss Narrows, Revenue Climbs; Q1, Full-Year 2024 Revenue Guidance Set MT
Transcript : CVRx, Inc., Q4 2023 Earnings Call, Jan 25, 2024
CVRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (CVRX) CVRX Posts Q4 Revenue $11.3M, vs. Street Est of $11.1M MT
CVRx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Lake Street Adjusts CVRx Price Target to $35 From $32, Maintains Buy Rating MT
Transcript : CVRx, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
CVRx Shares Drop; CEO to Retire; Preliminary Q4, 2023 Revenue Top Consensus; Q1 Forecast Issued MT
CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer CI
CVRx, Inc. Announces Nadim Yare Retires as President CI
CVRx, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023 and First Quarter and Full Year of 2024 CI
Lake Street Raises CVRx Price Target to $32 From $21, Maintains Buy Rating MT
CVRx Gets FDA Approval for Expanded Labeling for Barostim MT
CVRx, Inc. Receives FDA Approval for Expanded Labing of Barostim CI
Craig Hallum Adjusts CVRx Price Target to $24 From $22, Maintains Buy Rating MT
Sector Update: Health Care Stocks Stronger Late Afternoon MT
Sector Update: Health Care Stocks Gain in Afternoon Trading MT
Sector Update: Health Care MT
CVRx Shares Rise as Medicare Increases Payment for Heart Failure Device Procedure MT
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast MT
CVRx Jumps Premarket After Boosting 2023 Revenue Guide, Trimming Operating Expenses Forecast; Q3 Net Loss Narrows MT
Transcript : CVRx, Inc., Q3 2023 Earnings Call, Oct 26, 2023
Chart CVRx, Inc.
More charts
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.69 USD
Average target price
34 USD
Spread / Average Target
+131.45%
Consensus